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Abstract
Acromegaly is a chronic disease with an important impact on patients, Health Related Quality of
Life (HRQoL). The ability to effectively measure Health Related Quality of Life is central to
describing the impacts of disease or treatment upon the patient, therefore the importance of having
a disease specific questionnaire for acromegaly. For the development of the AcroQoL
questionnaire different sources of information were used: first a literature search was performed
to identify relevant papers describing the impact of acromegaly in HRQoL, second the main
domains of impact on HRQoL were identified by 10 experts endocrinologists, and third ten in-
depth semi-structured interviews were conducted in acromegalic patients to identify domains and
items related to the self-perceived impact of acromegaly in patients' life. After a proper qualitative
analysis a preliminary 38 item questionnaire was obtained. Rasch analysis concluded with a final 22
item questionnaire. The measurement properties (validity and reliability) of the resulting final
questionnaire were tested and compared using standard procedures (Cronbach's Alpha and item-
total correlation). The evaluation of the item parameters confirmed the construct validity of the
new instrument. Responsiveness to change was assessed in a small sample of 32 acromegalic
patients with active disease in Spain who were administered the AcroQoL and the generic
questionnaire EuroQoL 5-D. The results showed a statistically significant relationship between all
the dimensions of AcroQoL and the VAS (visual analogic scale) of EQ-5D. An improvement in the
global score of AcroQoL was related to a global improvement in the VAS of the EQ-5D.
Following the current recommended standard methodology the Spanish questionnaire was
translated into eleven other languages.
Review
Why assess Health Related Quality of Life in patients with 
Acromegaly?
Any health problem may place significant restrictions on
the normal development of physical, emotional and
social aspects of a patient's life. The increasing interest in
measures reflecting the personal viewpoint of patients'
health has led to an extended demand for reliable and
valid standardized questionnaires of Health-Related
Quality of Life (HRQoL) [1].
Although the use of HRQoL questionnaires is more com-
mon in clinical research, their use in clinical practice can
also help clinicians to obtain standardized information
on the impact of the disease and its treatment on patients'
HRQOL; information that cannot be obtained using
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traditional measures, and that could be of a great use in
clinical decision making.
Taking into account features like item content, scope and
target population, instruments can basically be classified
as generic or disease-specific [2]. Disease-specific ques-
tionnaires, those that only contain items specifically
designed for a particular condition, are more likely to be
relevant and sensitive to patients in areas that clinicians
may wish to monitor.
Acromegaly, excessive growing hormone (GH) secretion,
is a rare affection with an annual incidence between 3 and
4 cases per million of people, being more common in
women [3]. Chronic effects of acromegaly are not only
disabling but also disfiguring [4]. Most acromegalic
patients present with 4–10 years' history of changes in fea-
tures, bony overgrowth, soft tissue swelling, tiredness,
skin changes as well as cardiovascular symptoms [5,6]. All
these factors make acromegaly a disease with considerable
impact on HRQOL. Furthermore, the correlation between
clinical severity and impact of disease on patients' lives is
weak; thus is important to include HRQOL as an outcome
measure. Dimensions such as body image, pain, depres-
sion, mood lability, energy and strength level, as well as
physical and mental drive, have been described as some of
the most important personal domains affected in patients
with acromegaly [7-10]. An instrument to assess HRQOL
in people suffering acromegaly can be very helpful to pro-
vide clinicians with an effective means to assess patients'
self-perceived status as well as to screen patients who
require appropriate further evaluation.
What is the AcroQoL?
The Acromegaly Quality of Life Questionnaire (ACRO-
QOL) is the first acromegaly-specific HRQOL measure
designed for use in clinical trials and for the routine mon-
itoring of patients diagnosed of acromegaly.
How was the AcroQoL developed?
The AcroQoL was originally developed in 2001 by X.
Badia and colleagues [11]. The strategy was to first carry
out a literature search to identify relevant papers describ-
ing the impact of acromegaly in HRQOL [7-9,12]. Dimen-
sions which appeared to be important in acromegaly
were: body image, depression, mood lability, pain, energy
and strength level, as well as physical and mental
domains. Secondly ten experienced endocrinologists were
asked to enumerate and identify those domains of
acromegaly they believed would cause problems in
patients' life. The domains considered important in the
assessment of the patient's perception of health in
acromegaly were: physical, psychological, social, capacity
to perform daily activities, symptoms, cognitive ability,
health perception, sleeping abnormalities, sexual func-
tion, energy/vitality, pain and body image. This informa-
tion allowed the identification of dimensions considered
important in the assessment of the patients' perception of
health.
Afterwards, 10 in-depth semi-structured interviews of
patients with acromegaly were obtained. The aim was to
determine those aspects of the parameters that were most
commonly cited by them as incapacitating in the achieve-
ment of their needs; they were specifically asked to
describe the areas of their lives that were influenced by
acromegaly with special emphasis on dimensions identi-
fied above. The interviews were conducted in an office by
a physician, were tape-recorded, took between 30 and 60
minutes and were later transcribed. From these tran-
scripts, a series of 204 items were obtained relevant to the
various involved domains. After eliminating items consid-
ered ambiguous, complicated to read, double-barrelled,
and also those with jargon terms, too long or negatively
worded, a first item reduction resulted in 142 items
drafted in question form.
A qualitative reduction of these items was then per-
formed. The criteria to include or exclude one of the 142
items analysed were based on the mean scoring given by
the experts for the three scales: "clarity of wording", "fre-
quency of occurrence", and "importance" among patients
with acromegaly, using a 1–5 Likert-type scale. A Spear-
man's correlation for the scoring obtained for the evalu-
ated items was calculated for clarity, frequency and
importance. Analysis of internal consistency was evalu-
ated with Cronbach's Alpha. Analysis of the results
allowed a further reduction where the items were listed
according to clarity. Items were considered for final inclu-
sion if clarity, frequency and importance were considered
high, if clarity and importance were high together with
low frequency, and also if frequency and importance were
high and clarity low; in this latter situation the item was
included but modified to enhance clarity.
A further qualitative review of the pre-selected items based
on prior experience with other similar instruments con-
cluded in the initial 38-item questionnaire. In order to
refine the instrument a further quantitative reduction was
performed with Rasch analysis (dichotomous logistic
response model) [13], using the answers to the question-
naire of a group of 72 patients with acromegaly from eight
different centres throughout Spain. The Rasch model con-
structs a line of measurement with the items placed hier-
archically and provides fit statistics to indicate just how
well different items describe the group of subjects
responding to a questionnaire [14]. A final 22-item ques-
tionnaire was obtained (Table 1). The measurement prop-
erties (validity and reliability) of the resulting final
questionnaire were tested and compared using standardHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/13
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procedures (Cronbach's Alpha and item-total correlation)
(Fig. 1).
Which translations are available?
The AcroQoL was originally developed and validated for
Spanish-speaking population. The Spanish original ques-
tionnaire was first translated into English following rec-
ommended standard methodology [15]. The Spanish
questionnaire was translated by two professional, bilin-
gual translators with a great deal of experience in translat-
ing HRQOL questionnaires; both translations were
compared with each other and with the original Spanish
version at a consensus meeting; if the translation was clear
and correct no changes were made; if there were doubts or
contrasting opinions with the project manager, a consen-
sus was reached after in-depth discussion, to produce the
first English version of the questionnaire. This version was
then independently translated back into Spanish to ascer-
tain equivalent significance in both languages. After a sec-
ond meeting, the second consensus English version was
produced, and presented to five English-speaking Austral-
ian patients with acromegaly to asses and correct for com-
prehension, clarity, cultural relevance and suitable
wording (cognitive debriefing), thus providing the final
English version of the AcroQoL questionnaire.
Afterwards the AcroQoL questionnaire has been trans-
lated into many other languages such as: Dutch, French,
German, Greek, Hungarian, Italian, Portuguese, Portu-
guese for Brazil, Swedish and Turkish following the same
procedure stated above.
Why is the AcroQoL a good instrument to consider using?
AcroQoL is a disease specific questionnaire for acromeg-
aly with good psychometric properties which were meas-
ured initially in a descriptive study with a sample of 72
patients throughout Spain. The item-total correlation and
the reliability and internal consistency evaluated by Cron-
bach's Alpha analysis of the different subscales of the 22
item questionnaire are expressed in Table 2. Both the
complete 22 item questionnaire and the two different
scales of eight and 14 item have a Cronbach's Alpha value
> 0.8, which indicates high reliability and internal
consistency.
A six month follow-up study was carried out in order to
measure responsiveness to change. A sample of 95
patients with acromegaly was obtained, 36 (37.9%) of
them were included in the group of responsiveness to
change, and 59 (62.1%) in the reliability group. Respon-
siveness to change after medical or surgical treatment was
measured in those patients with active acromegaly, and
compared with the results of the EuroQoL 5-D question-
naire. The results showed a statistically significant rela-
tionship between all the dimensions of AcroQoL and the
VAS of the EQ-5D. Therefore an improvement in the glo-
bal score of AcroQoL is related to a global improvement
in HRQoL (Table 3).
The feasibility of the questionnaire showed to be over
95%.
What are the applications of the AcroQoL?
AcroQoL is a simple and valid specific instrument to
assess HRQOL in people suffering acromegaly aged 18 to
70 years. It can be used in two different fields: in clinical
trials of new drugs, and in the monitoring of patients in
clinical practice. This is to assess patients' self-perceived
status as well as to be used as an instrument to screen
patients who require appropriate further evaluation due
to its good responsiveness to change. The longitudinal
assessment of HRQOL of patients suffering acromegaly
will increase the knowledge of the impact of the disease
on patient perception of well-being and functioning. This
is particularly useful in the evaluation of intervention or
treatment effects.
Table 1: The final AcroQoL questionnaire
Item
1 My legs are weak*
2 I feel ugly**
3 I get depressed*
4 I look awful in photographs**
5 I avoid going out very much with friends because of my 
appearance***
6 I try to avoid socializing***
7 I look different in the mirror**
8 I feel rejected by people because of my illness***
9 I have problems carrying out my usual activities*
10 People stare at me because of my appearance***
11 Some part of my body (nose, feet, hands,...) are too big**
12 I have problems doing things with my hands, for example, 
sewing or handling tools**
13 The illness affects my performance at work or in my usual 
tasks*
14 My joints ache*
15 I am usually tired*
16 I snore at night**
17 It is hard for me to articulate words due to the size of my 
tongue**
18 I have problems with sexual relationships***
19 I feel like a sick person*
20 The physical changes produced by my illness govern my life***
21 I have little sexual appetite***
22 I feel weak*
Frequency of occurrence (always, most of the time, sometimes, rarely, 
never) or degree of agreement with the items (completely agree, 
moderately agree, neither agree nor disagree, moderately disagree, 
completely disagree) are the response choices. * Scale 1 (Physical) ** 
Scale 2-1 (Psychological/ appearance) *** Scale 2-2 Psychological/ 
personal relations)Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/13
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Development of the AcroQoL questionnaire Figure 1
Development of the AcroQoL questionnaire
Table 2: Reliability and consistency of the different scales of the AcroQoL
Scales Cronbach's Alpha Item-total correlation
Initial (38) items 0.94 0.34–0.79
Final (22) items) 0.91 0.31–0.77
Physical Scale (8 items) 0.90 0.60–0.78
Psychological Scale (14 items) 0.84 0.31–0.66
Psychological / appearance (seven items) 0.80 0.42–0.65
Psychological/ personal relations (seven items) 0.76 0.44–0.61Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/13
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AcroQoL, as a disease-specific questionnaire, evaluates
those dimensions that have been described to specifically
affect to patients with acromegaly, therefore it detects
morbidity that could be missed by generic tools. Never-
theless when the aim is to evaluate new interventions it's
desirable to use AcroQoL together with a generic ques-
tionnaire, such us PGWBS [16], in order to cover new
dimensions of quality of life that haven't been described
as important in the acromegalic patients.
What areas of health does it measure?
The questionnaire is uni-dimensional and contains 22
items divided in two scales: one that evaluates physical
aspects (eight items) and another one that evaluates psy-
chological aspects (14 items). This last one is also divided
in two sub-scales: one of them that evaluates physical
appearance, and another one that evaluates the impact of
the disease on the personal relationships of the patient
(seven items each).
Who answers it?
AcroQoL is a self administered questionnaire. Only in
those cases where the patient has some difficulties in read-
ing, the questionnaire can be read by the investigator and
answered as an interview.
How long does it take to complete the AcroQoL 
questionnaire?
It takes about five minutes to answer the questionnaire.
How is the AcroQoL scored?
Each of the 22 items of the AcroQoL is answered in a 1 to
5 Likert scale measuring either the frequency of occur-
rence (always, most of the time, sometimes, rarely, or
never) or the degree of agreement with the items (com-
pletely agree, moderately agree, neither agree nor disagree,
moderately disagree, completely disagree). A global score
is obtained adding the results of the 22 items using the
following formula:
where X is the sum of the answers (between 1 and 5 for
each answer) (from a minium of 22 – worse QoL – until
110 – best QoL –).
Is the AcroQoL responsive to change?
As it has been explained before AcroQoL has demon-
strated to be responsive to change. In a sample of 36
patients an improvement in the global score of AcroQoL
showed to be related to a global improvement in HRQoL
measured by EVA-scale in EQ-5D (Table 3).
In which populations has AcroQoL been used?
The acromegaly-specific questionnaire has been used in
patients aged 18 to 70 years who have been diagnosed of
acromegaly thoroughout Spain. Even though it has been
translated to many other languages, we are not aware, at
the moment, of any other original publications using the
AcroQoL questionnaire.
Who may I contact to obtain a copy of AcroQoL?
If you wish to get a copy of the questionnaire please
contact:
Xavier Badia
Health Outcomes Research Europe
C/ Plató 6, 1o, 5a
08021 Barcelona, Spain
Tel: +34 93 209 3257
Fax: +34 93 241 2710
Email: .xbadia@hor-europe.com
Table 3: Responsiveness to change of AcroQoL questionnaire comparing basal scoring and after six months follow-up
Basal 6 months Difference N P Effect size
Mean SD Mean SD Mean SD
Global 52.84 19.52 67.97 18.46 15.13 17.23 28 P < 0.0001 -0.775
Physical 49.17 22.03 65.99 21.16 16.81 19.74 34 P < 0.0001 -0.764
Body image 44.23 21.87 58.29 22.68 14.05 23.99 31 P = 0.0028 -0.643
Personal relationships 69.58 20.19 78.22 16.34 8.64 15.75 31 P = 0.0047 -0.428
VAS of EQ-5D 60.33 19.87 74.30 16.72 13.97 18.55 33 P = 0.0002
(
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Susan Webb
Endocrinology Department
Hospital de la Santa Creu i Sant Pau
Sant Antoni MaClaret, 167
08025 Barcelona, Spain
Tel: +34 93 291 9042
Fax: +34 93 291 9270
Email: swebb@santpau.es
How can we obtain a scientific support during our study?
If you need any additional support about how to work
with the AcroQoL questionnaire please contact the same
addresses as above.
Conclusions
AcroQoL is a self-administered disease specific question-
naire to measure quality of life in patients with acromeg-
aly. It contains 22 items divided in two scales that
measure physical and psychological aspects. The valida-
tion process demonstrated the questionnaire to have high
internal consistency, reliability and responsiveness to
change, therefore is a useful tool to be used in clinical tri-
als as well as in the monitoring of patients in the clinical
practice. It has been translated into eleven other
languages.
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